	US 12,128,077 B2
	Strains, composition and method of use
Charlotte Vedel, Copenhagen O (DK); Ida Blomquist Jorgensen, Copenhagen (DK); and Soren Kjaerulff, Copenhagen (DK)
Assigned to L'Oreal S.A., Paris (FR)
Appl. No. 17/417,654
Filed by Lactobio A/S, Copenhagen O (DK)
PCT Filed Aug. 8, 2019, PCT No. PCT/EP2019/071348 § 371(c)(1), (2) Date Jun. 23, 2021, PCT Pub. No. WO2020/098988, PCT Pub. Date May 22, 2020.
Claims priority of application No. PA 2019 00009 (DK), filed on Jan. 4, 2019; and application No. PA 2019 00469 (DK), filed on Apr. 17, 2019.
Prior Publication US 2022/0110986 A1, Apr. 14, 2022
Int. Cl. A61K 39/02 (2006.01); A61K 35/747 (2015.01); A61P 31/04 (2006.01); C12N 1/20 (2006.01); C12R 1/225 (2006.01)

CPC A61K 35/747 (2013.01) [A61P 31/04 (2018.01); C12N 1/205 (2021.05); C12R 2001/225 (2021.05)]

15 Claims

1. A bacterial strain capable of treating, alleviating, suppressing, prophylaxis, and/or preventing growth of a pathogenic micro-organism wherein the one or more bacterial strain is Lactobacillus plantarum LB356R, which is deposited as DSM 33094 or Lactobacillus plantarum LB244R, which is deposited as DSM 32996, and wherein the one or more bacterial strains is provided as one or more viable strains, one or more dead or inactivated strains, one or more strain lysate: one or more strain metabolites or a combination hereof, or wherein the viable bacterial strain is provided in an encapsulated, micro-encapsulated, spray-dried and/or lyophilized form.